Wednesday, September 18, 2019

Predictive Oncology Inc. (NASDAQ: POAI) Utilizes Proprietary Dataset to Revolutionize Treatment Outcomes for Cancer


  • Predictive Oncology is working to develop highly customizable assessment methods to individualize treatment options for cancer, improving outcomes
  • POAI’s innovative technology is pioneering in the field of individualizing treatment for ovarian cancer
  • Predictive Oncology offers potential for significant ROI as it focuses on improving outcomes for cancer patients of today and tomorrow
Predictive Oncology Inc. (NASDAQ: POAI) is harnessing its unique, proprietary database of cancer cases using the proven power of artificial intelligence (AI) to revolutionize treatment outcomes for cancer patients. The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied to both individualize current therapies and develop the next generation of precision therapies, leading to better outcomes for patients. The company recently announced a corporate name change from Precision Therapeutics to Predictive Oncology Inc., which reflects its mission and strategic emphasis.

Predictive Oncology seeks to revolutionize the way cancer is treated for both the patients of today and those of tomorrow. The company is well positioned to do exactly that as a result of two key assets: its ability to grow patients’ own tumors in the laboratory and test the tumors’ responses to chemotherapy, together with its existing database of outcome data cataloguing more than 150,000 tumors and their specific responses to those chemotherapies.

POAI’s innovative technology enables the company to be a pioneer in the field of precision oncology, putting the patient at the heart of both selecting treatments and the development of new treatments. While the use of AI in precision medicine has been improving oncologists’ ability to diagnose cancer for several years (http://ibn.fm/ZsmGN), the ability to accurately prescribe the correct treatment for all but a few patients has been absent. Applying a guess-and-check methodology, doctors have limited ability to prescribe the most effective drug to treat patients. This approach relegates patients with cancer to the role of guinea pigs, trying new drugs and waiting to see the extent to which they are effective.

Oncologists are realizing that knowledge of genomics, or simply knowing the genetic markers of a tumor, is not enough to beat cancer. The ability to better predict which drugs affect certain types of cancer vastly improves the efficacy of oncologists’ recommendations. This is the void POAI’s technology can fill.

By utilizing its rich base of data, which includes not only diagnostic/genomic information but also unique response data which indicates how certain cancer types have responded to certain drugs, POAI’s predictive models guide doctors to more effectively individualize therapy. Without having to wait to discover if the patient responds to a drug, POAI’s technology is giving cancer patients an earlier indication of efficacy, and hence more favorable odds for recovery, without squandering their time, a commodity that many patients don’t have.

In addition, the company has been working with two major partners to validate its predictive models: Interpace Diagnostics Group Inc. and UPMC Magee-Women’s Hospital. While primarily utilizing its technology to create a predictive model for ovarian cancer, POAI’s goal is to grow, applying its methodologies and leveraging its huge database to impact cancers such as breast, colon and others.

POAI came about as an acquisition between Skyline Medical and Helomics. Helomics applies AI to its rich data gathered from patient tumors to customize cancer therapies for individual patients and drive the development of new targeted therapies in collaboration with pharmaceutical firms.

In addition, POAI’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory. This process essentially “fools” cancer cells into thinking they are still growing inside a patient. TumorGenesis’ approach is expected to provide a much more relevant model of patients’ tumors that may be used for testing of drugs, personalized therapy or the development of new drugs.

Based in Eagan, Minnesota, POAI operates via three business units: Helomics, TumorGenesis and Skyline Medical. Predictive Oncology continues to take advantage of the synergies of its subsidiaries to bring precision medicine to the treatment of cancer. The company is at the vanguard of innovation in using AI in precision cancer treatment. For investors, Predictive Oncology offers the potential for significant ROI as it focuses on improving patient outcomes.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html